{"id":"meropenem-infusion","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Diarrhea"},{"rate":"3-8%","effect":"Nausea"},{"rate":"1-5%","effect":"Vomiting"},{"rate":"2-5%","effect":"Headache"},{"rate":"2-4%","effect":"Phlebitis at injection site"},{"rate":"1-3%","effect":"Rash"},{"rate":"<1%","effect":"Seizures"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Meropenem is a carbapenem antibiotic that penetrates bacterial cell walls and binds to penicillin-binding proteins, inhibiting cross-linking of peptidoglycan and leading to cell wall degradation and bacterial death. It has activity against a wide range of gram-positive and gram-negative bacteria, including anaerobes, making it effective for serious infections caused by susceptible organisms.","oneSentence":"Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:34.407Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated intra-abdominal infections"},{"name":"Bacterial meningitis"},{"name":"Complicated skin and soft tissue infections"},{"name":"Febrile neutropenia"},{"name":"Nosocomial pneumonia"},{"name":"Urinary tract infections"}]},"trialDetails":[{"nctId":"NCT07484633","phase":"PHASE4","title":"A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients.","status":"NOT_YET_RECRUITING","sponsor":"Semmelweis University","startDate":"2026-04","conditions":"Infection, Sepsis, NICU","enrollment":110},{"nctId":"NCT06087536","phase":"PHASE2","title":"A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex","status":"RECRUITING","sponsor":"Omnix Medical Ltd","startDate":"2026-03","conditions":"Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia","enrollment":54},{"nctId":"NCT07327619","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-01-22","conditions":"Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia","enrollment":420},{"nctId":"NCT07326540","phase":"PHASE3","title":"Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex","status":"NOT_YET_RECRUITING","sponsor":"BioVersys SAS","startDate":"2026-03-20","conditions":"Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP), Colistin Resistanrt ABC","enrollment":248},{"nctId":"NCT06672978","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis","status":"RECRUITING","sponsor":"Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)","startDate":"2025-06-03","conditions":"Acute Pyelonephritis, Complicated Urinary Tract Infection","enrollment":66},{"nctId":"NCT06602245","phase":"","title":"Clearance of Antibacterial Agents During Hemoperfusion in Patients With Sepsis","status":"COMPLETED","sponsor":"Efferon JSC","startDate":"2024-10-21","conditions":"Sepsis, Septic Shock","enrollment":30},{"nctId":"NCT03543436","phase":"PHASE3","title":"Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-01-04","conditions":"Urinary Tract Infections","enrollment":29},{"nctId":"NCT07096310","phase":"PHASE1, PHASE2","title":"Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ain Shams University","startDate":"2024-01-01","conditions":"Sepsis","enrollment":400},{"nctId":"NCT06916156","phase":"PHASE1","title":"Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants","status":"COMPLETED","sponsor":"Antabio","startDate":"2025-04-28","conditions":"Pharmacokinetics Study on Healthy Volunteers Adults","enrollment":26},{"nctId":"NCT07122596","phase":"PHASE4","title":"EFFICACY OF PROLONGED INFUSION MEROPENEM IN CRITICALLY ILL PAEDIATRIC INTENSIVE CARE PATIENTS","status":"COMPLETED","sponsor":"Pakistan Navy Station Shifa Hospital","startDate":"2024-04-01","conditions":"Sepsis, Bacterial Infection","enrollment":150},{"nctId":"NCT03452839","phase":"PHASE4","title":"Bolus Versus Continuous Infusion of Meropenem","status":"COMPLETED","sponsor":"Università Vita-Salute San Raffaele","startDate":"2018-06-05","conditions":"Antibiotic Resistant Infection, Critical Illness","enrollment":607},{"nctId":"NCT05922124","phase":"PHASE4","title":"Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2024-09-01","conditions":"Carbapenem Resistant Bacterial Infection, Acinetobacter Bacteremia, Acinetobacter Pneumonia","enrollment":734},{"nctId":"NCT07089186","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-04-12","conditions":"Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP), Complicated Intra-abdominal Infection (cIAI)","enrollment":80},{"nctId":"NCT06527677","phase":"PHASE1","title":"Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects","status":"COMPLETED","sponsor":"Antabio","startDate":"2024-07-19","conditions":"Renal Impairment","enrollment":41},{"nctId":"NCT02687906","phase":"PHASE1","title":"Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)","startDate":"2016-07","conditions":"Bacterial Infections","enrollment":39},{"nctId":"NCT06184659","phase":"PHASE4","title":"Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis","status":"RECRUITING","sponsor":"Scandinavian Critical Care Trials Group","startDate":"2025-06-26","conditions":"Sepsis, Septic Shock","enrollment":5800},{"nctId":"NCT06051513","phase":"NA","title":"Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection","status":"RECRUITING","sponsor":"Southeast University, China","startDate":"2023-11-27","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":404},{"nctId":"NCT05578586","phase":"NA","title":"A Pilot Study for Optimizing Meropenem Administration in the ICU","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2021-12-14","conditions":"Drug Effect","enrollment":50},{"nctId":"NCT06818565","phase":"NA","title":"Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-02-10","conditions":"Acute-On-Chronic Liver Failure","enrollment":150},{"nctId":"NCT02820987","phase":"PHASE3","title":"PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2016-09-27","conditions":"Septic Shock","enrollment":119},{"nctId":"NCT06739382","phase":"PHASE3","title":"Management of Ventilation Acquired Pneumonia Caused by Pseudomonas and Acinetobacter Organisms in a Pediatric Center","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2021-01-01","conditions":"Ventilation Acquired Pneumonia","enrollment":64},{"nctId":"NCT03329092","phase":"PHASE3","title":"A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-04-05","conditions":"Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia","enrollment":422},{"nctId":"NCT06419296","phase":"","title":"Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.","status":"COMPLETED","sponsor":"Hospital Italiano de Buenos Aires","startDate":"2024-06-01","conditions":"Bacteremia","enrollment":265},{"nctId":"NCT04882085","phase":"PHASE4","title":"Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-26","conditions":"Urinary Tract Infection, Acute Pyelonephritis, Hospital Acquired Pneumonia","enrollment":60},{"nctId":"NCT06633718","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-10-31","conditions":"Intra-abdominal Infections","enrollment":786},{"nctId":"NCT05784844","phase":"PHASE4","title":"Antimicrobial Revision in Persistent Febrile Neutropenia","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2024-08","conditions":"Febrile Neutropenia","enrollment":""},{"nctId":"NCT06293677","phase":"PHASE4","title":"Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2024-03-01","conditions":"Febrile Neutropenia","enrollment":30},{"nctId":"NCT05905913","phase":"PHASE1","title":"FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects","status":"COMPLETED","sponsor":"Antabio","startDate":"2023-04-12","conditions":"Healthy Volunteers","enrollment":72},{"nctId":"NCT03897582","phase":"","title":"Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study","status":"RECRUITING","sponsor":"Centre Hospitalier de Valenciennes","startDate":"2019-02-22","conditions":"Beta-lactam, Continuous Renal Replacement Therapy, Pneumonia","enrollment":65},{"nctId":"NCT06198764","phase":"PHASE3","title":"A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-07-06","conditions":"Mental Health Issue","enrollment":80},{"nctId":"NCT04809259","phase":"EARLY_PHASE1","title":"Ambulatory Administration of Meropenem With Elastomeric Pumps and an Isothermal Pouch","status":"UNKNOWN","sponsor":"University of Lausanne Hospitals","startDate":"2024-01-01","conditions":"Infection, Bacterial","enrollment":30},{"nctId":"NCT05102162","phase":"PHASE4","title":"BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia","status":"TERMINATED","sponsor":"University of Florida","startDate":"2021-12-17","conditions":"Pneumonia","enrollment":35},{"nctId":"NCT03630081","phase":"PHASE3","title":"Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","status":"UNKNOWN","sponsor":"Wockhardt","startDate":"2024-01","conditions":"Complicated Urinary Tract Infection, Acute Pyelonephritis","enrollment":1004},{"nctId":"NCT03230838","phase":"PHASE2","title":"MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-04-26","conditions":"Complicated Urinary Tract Infection, Pyelonephritis","enrollment":134},{"nctId":"NCT00621192","phase":"PHASE1, PHASE2","title":"Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections","status":"COMPLETED","sponsor":"The Emmes Company, LLC","startDate":"2008-06","conditions":"Necrotizing Enterocolitis, Intra-abdominal Infection","enrollment":200},{"nctId":"NCT05565222","phase":"PHASE3","title":"Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-03-11","conditions":"Sepsis, Septic Shock","enrollment":600},{"nctId":"NCT03108690","phase":"PHASE4","title":"Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia","status":"WITHDRAWN","sponsor":"Sara Thønnings","startDate":"2017-10-01","conditions":"Bacteremia","enrollment":""},{"nctId":"NCT05204368","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)","status":"UNKNOWN","sponsor":"Evopoint Biosciences Inc.","startDate":"2023-03-30","conditions":"Complicated Urinary Tract Infection Including Acute Pyelonephritis","enrollment":780},{"nctId":"NCT03830333","phase":"PHASE3","title":"Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-03-20","conditions":"Complicated Intra-abdominal Infections","enrollment":268},{"nctId":"NCT05393505","phase":"PHASE4","title":"Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-10-24","conditions":"Neutropenic Fever","enrollment":344},{"nctId":"NCT04799626","phase":"","title":"Population Pharmacokinetics and Dosage Individualization of Antibiotics in Elderly Patients","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-04-01","conditions":"Elderly Infection","enrollment":500},{"nctId":"NCT03440216","phase":"NA","title":"Population Pharmacokinetics and Pharmacodynamics of Beta-lactams of Interest in Adult Patients From Intensive Care Units","status":"UNKNOWN","sponsor":"Université Catholique de Louvain","startDate":"2018-03-15","conditions":"Pharmacokinetics, Anti-Bacterial Agents, Infection, Bacterial","enrollment":20},{"nctId":"NCT05340530","phase":"PHASE1","title":"To Evaluate the Pharmacokinetic Effects of TQD3606 for Injection in Healthy Adult Subjects","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-04","conditions":"Infections","enrollment":56},{"nctId":"NCT05060419","phase":"PHASE2","title":"Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2021-10-08","conditions":"Complicated Urinary Tract Infection, Acute Pyelonephritis","enrollment":150},{"nctId":"NCT05042271","phase":"","title":"PK of Meropenem in Patients on Plasma Exchange","status":"UNKNOWN","sponsor":"Prince of Songkla University","startDate":"2020-01-01","conditions":"Autoimmune Diseases","enrollment":15},{"nctId":"NCT03019965","phase":"NA","title":"Efficacy of Betalactam Antibiotics in Prolonged Infusion Compared to Intermittent in Pediatric Patients With Sepsis","status":"COMPLETED","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2017-02-01","conditions":"Sepsis","enrollment":426},{"nctId":"NCT04816968","phase":"PHASE1","title":"Antibiotics Continuous Infusion at Home","status":"UNKNOWN","sponsor":"Ospedale San Carlo Borromeo","startDate":"2021-09","conditions":"Severe Bacterial Infections","enrollment":50},{"nctId":"NCT04764058","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Colistin Based Antibiotic Therapy","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2017-09-01","conditions":"Septicemia, Bacterial Infections","enrollment":60},{"nctId":"NCT04233996","phase":"PHASE4","title":"Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Hematologic Patients","status":"UNKNOWN","sponsor":"Hospital Universitari de Bellvitge","startDate":"2019-06-05","conditions":"Febrile Neutropenia","enrollment":150},{"nctId":"NCT04489459","phase":"PHASE4","title":"Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae","status":"UNKNOWN","sponsor":"Al-Azhar University","startDate":"2019-09-21","conditions":"Treatment of Blood Stream Infections Due to Multidrug-Resistant Klebsiella Pneumoniae","enrollment":60},{"nctId":"NCT02795949","phase":"PHASE3","title":"Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2016-10","conditions":"Enterobacteriaceae Infections","enrollment":344},{"nctId":"NCT04402359","phase":"","title":"Usage of Meropenem/Gentamicin Versus Ceftazidime/Avibactam in ARDS","status":"COMPLETED","sponsor":"King Abdul Aziz Specialist Hospital","startDate":"2018-07-05","conditions":"Ventilator Associated Pneumonia","enrollment":200},{"nctId":"NCT03645668","phase":"PHASE4","title":"Efficacy and Pharmacokinetics of Meropenem in Severe Septic Patients","status":"COMPLETED","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-01-30","conditions":"Sepsis","enrollment":80},{"nctId":"NCT03915236","phase":"NA","title":"Approach for Optimizing Meropenem Therapy in Intubated and Mechanically-Ventilated, Adult Patients With Severe Gram-Negative Lower Respiratory Tract Infection","status":"TERMINATED","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2019-02-18","conditions":"Lower Respiratory Tract Infection","enrollment":7},{"nctId":"NCT04257838","phase":"","title":"Monitoring of Piperacillin-Tazobactam and Meropenem Plasmatic Levels in Critical Patients","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2020-02-15","conditions":"Sepsis, Septic Shock","enrollment":200},{"nctId":"NCT03477422","phase":"PHASE3","title":"CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria","status":"COMPLETED","sponsor":"Venus Remedies Limited","startDate":"2014-01-11","conditions":"Urinary Tract Infection Complicated, Acute Pyelonephritis","enrollment":230},{"nctId":"NCT02142751","phase":"PHASE3","title":"Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2014-07","conditions":"Infection Due to ESBL Escherichia Coli","enrollment":161},{"nctId":"NCT03344627","phase":"NA","title":"Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-11-27","conditions":"Sepsis, Septic Shock, Critical Illness","enrollment":76},{"nctId":"NCT03006679","phase":"PHASE3","title":"A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia","status":"WITHDRAWN","sponsor":"Melinta Therapeutics, Inc.","startDate":"2018-08","conditions":"Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia, Hospital-Acquired Pneumonia","enrollment":""},{"nctId":"NCT01445678","phase":"PHASE3","title":"Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2011-12-23","conditions":"Complicated Intra-abdominal Infection","enrollment":494},{"nctId":"NCT01147640","phase":"PHASE2","title":"Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-06-25","conditions":"Complicated Intra-abdominal Infection","enrollment":122},{"nctId":"NCT01970371","phase":"PHASE3","title":"A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)","status":"COMPLETED","sponsor":"Achaogen, Inc.","startDate":"2014-09-16","conditions":"Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE, Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE","enrollment":69},{"nctId":"NCT02486627","phase":"PHASE3","title":"A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)","status":"COMPLETED","sponsor":"Achaogen, Inc.","startDate":"2016-01-11","conditions":"Complicated Urinary Tract Infection, Acute Pyelonephritis","enrollment":609},{"nctId":"NCT02475733","phase":"PHASE2","title":"Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-08-01","conditions":"Complicated Intra-abdominal Infections","enrollment":83},{"nctId":"NCT02166476","phase":"PHASE3","title":"Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2014-11-20","conditions":"Urinary Tract Infection Complicated, Acute Pyelonephritis","enrollment":550},{"nctId":"NCT03182504","phase":"PHASE1","title":"A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-06-15","conditions":"Gram-negative Bacterial Infections","enrollment":21},{"nctId":"NCT01429259","phase":"PHASE4","title":"Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children","status":"COMPLETED","sponsor":"Joseph Kuti","startDate":"2012-02","conditions":"Cystic Fibrosis, Pneumonia, Pseudomonas Aeruginosa Infection","enrollment":30},{"nctId":"NCT01381562","phase":"PHASE2","title":"GSK2251052 in the Treatment of Complicated Intra-abdominal Infections","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-10-03","conditions":"Infections, Intestinal","enrollment":15},{"nctId":"NCT01570192","phase":"PHASE2","title":"Clinical Trials to Reduce the Risk of Antimicrobial Resistance","status":"TERMINATED","sponsor":"University of Florida","startDate":"2010-09","conditions":"Bacterial Pneumonia","enrollment":43},{"nctId":"NCT01726023","phase":"PHASE3","title":"Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-01","conditions":"Complicated Intra-abdominal Infection","enrollment":486},{"nctId":"NCT00050401","phase":"PHASE3","title":"Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-07","conditions":"Pneumonia","enrollment":500},{"nctId":"NCT02732327","phase":"PHASE2","title":"Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2016-05-17","conditions":"Neoplasms, Febrile Neutropenia","enrollment":2},{"nctId":"NCT02972255","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-10-31","conditions":"Healthy Volunteers","enrollment":46},{"nctId":"NCT01667094","phase":"PHASE4","title":"A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis","status":"UNKNOWN","sponsor":"The Alfred","startDate":"2012-09","conditions":"Cystic Fibrosis","enrollment":50},{"nctId":"NCT00771316","phase":"PHASE3","title":"Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection (0826-054)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-12","conditions":"Urinary Tract Infections","enrollment":6},{"nctId":"NCT02048163","phase":"","title":"Intermittent Versus Continuous Infusion Meropenem in Cystic Fibrosis","status":"WITHDRAWN","sponsor":"Dayton Children's Hospital","startDate":"2013-12","conditions":"Cystic Fibrosis","enrollment":""},{"nctId":"NCT01292031","phase":"PHASE3","title":"Trial of Colistin Versus Meropenem in Ventilator-associated Pneumonia (VAP) (CR-GNB)","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2012-05","conditions":"Ventilator-associated Bacterial Pneumonia","enrollment":232},{"nctId":"NCT02615041","phase":"PHASE4","title":"The Pharmacodynamics of Meropenem in Patient With Ventilator-associated Pneumonia","status":"COMPLETED","sponsor":"Sutep Jaruratanasirikul","startDate":"2004-01","conditions":"Ventilator-Associated Pneumonia","enrollment":9},{"nctId":"NCT00891423","phase":"NA","title":"A Study of Meropenem Standard 30 Minute Infusion Versus Prolonged 3 Hour Infusion in Intensive Care Unit (ICU) Patients","status":"COMPLETED","sponsor":"Austin Health","startDate":"2009-04","conditions":"Sepsis","enrollment":10},{"nctId":"NCT02503761","phase":"PHASE3","title":"Bolus Versus Prolonged Infusion of Meropenem in Newborn With Late Onset Sepsis","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2013-08","conditions":"Late Onset Neonatal Sepsis","enrollment":100},{"nctId":"NCT02463747","phase":"PHASE4","title":"Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2015-06","conditions":"Fever, Febrile Neutropenia","enrollment":110},{"nctId":"NCT01158937","phase":"NA","title":"Pharmacokinetic Study of Extended Infusion Meropenem in Adult Cystic Fibrosis Patients","status":"TERMINATED","sponsor":"Unity Health Toronto","startDate":"2010-05","conditions":"Cystic Fibrosis Pulmonary Exacerbation","enrollment":2},{"nctId":"NCT01551394","phase":"PHASE3","title":"Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days With Clinical or Confirmed Late-onset Sepsis","status":"COMPLETED","sponsor":"PENTA Foundation","startDate":"2012-09","conditions":"Sepsis","enrollment":272},{"nctId":"NCT02344563","phase":"PHASE4","title":"Bioequivalence of Two Formulations of Meropenem Intravenous Injection","status":"COMPLETED","sponsor":"Yung Shin Pharm. Ind. Co., Ltd.","startDate":"2014-09","conditions":"Healthy","enrollment":14},{"nctId":"NCT01455246","phase":"PHASE2, PHASE3","title":"Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis","status":"TERMINATED","sponsor":"University of Padova","startDate":"2010-10","conditions":"Cirrhosis, Ascites, Nosocomial Spontaneous Bacterial Peritonitis","enrollment":32},{"nctId":"NCT02213796","phase":"PHASE4","title":"Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units","status":"COMPLETED","sponsor":"Sutep Jaruratanasirikul","startDate":"2013-01","conditions":"Initial Phase of Severe Sepsis and Septic Shock","enrollment":9},{"nctId":"NCT02191475","phase":"PHASE2, PHASE3","title":"Effect Study of Tigecycline to Treat Severe Sepsis and Septic Shock","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2014-05","conditions":"Abdominal Infection","enrollment":100},{"nctId":"NCT01110382","phase":"PHASE3","title":"A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-12","conditions":"Abscess, Intra-Abdominal, Abdominal Abscess, Abdomen, Acute","enrollment":41},{"nctId":"NCT00435305","phase":"","title":"Steady State Serum and Epithelial Lining Fluid (ELF) Antibiotics Concentrations Under Continous Infusion","status":"TERMINATED","sponsor":"University Hospital Tuebingen","startDate":"2006-11","conditions":"Pneumonia, Bacteremia","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Meropenem or Merrem(R)"],"phase":"marketed","status":"active","brandName":"Meropenem Infusion","genericName":"Meropenem Infusion","companyName":"Unity Health Toronto","companyId":"unity-health-toronto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Serious bacterial infections including intra-abdominal infections, Bacterial meningitis, Lower respiratory tract infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}